Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
about
Imaging biomarker roadmap for cancer studiesBrain Vascular Imaging TechniquesMonitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study.Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal CancerChanges in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome.Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.Functional MRI and CT biomarkers in oncology.Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.Vascular endothelial growth factor (VEGF), mast cells and inflammation.Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab.T1 in high-grade glioma and the influence of different measurement strategies on parameter estimations in DCE-MRI.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas
P2860
Q30242020-87539EDF-211E-4D65-B9A5-D91953CE6791Q30363574-7A369EE7-EE52-4F2B-82DC-08271F0BF35DQ32176092-81D927AC-F253-4B03-92FC-A188DA648FBCQ33770680-50F849EC-E7D9-4DF4-B96C-4D681C5D99D4Q34465123-640462F4-DAD9-4B1D-9056-032597B51222Q35869753-B77CC8B7-FD37-4854-8D6B-E009CA09FF04Q37185773-A263C36C-9FB4-4077-9380-954F35CECA85Q37221629-003B4128-4EDA-48BC-92B4-2976DB5944EEQ37492118-B2E749D3-430A-44B8-94CF-5D1689647071Q37496863-2398F371-516E-499F-BB8C-07FB88B2788AQ38171376-B4CC1085-4A4D-4A6C-878B-1ADB39932AD6Q38314429-860BA59A-DE7F-4A96-9B03-B40A7C2AC898Q39510882-3CF86A55-6E3E-4BDA-B704-E582E5D63030Q44817598-74F68864-BCC9-44F2-958A-5BE4703701ABQ47108263-54F90C8F-26E9-48DA-8A46-BD11BDB15A9CQ47367815-8EDFFF8F-31F4-4AE8-A20B-260605AE002AQ47731005-9E0388BC-D96C-4BC6-A53D-BB305D0123CCQ48469860-ADFCD2FB-5C9A-43E2-803E-3C764D7C56D7Q48473104-F672D766-D5B0-4CBC-9770-204865660A4CQ57177114-D2E75130-FDA6-4565-A79B-97DD5B796050
P2860
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
@ast
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
@en
type
label
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
@ast
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
@en
prefLabel
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
@ast
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
@en
P1476
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?
@en
P2093
Gordon C Jayson
James P B O'Connor
P304
P356
10.1158/1078-0432.CCR-12-1501
P407
P577
2012-10-23T00:00:00Z